The Influence of Antidepressants on the Disease Course Among Patients With Crohn’s Disease and Ulcerative Colitis—A Danish Nationwide Register–Based Cohort Study

Marie Skov Kristensen, MSc, RN* Thora Majlund Kjærulff, MSc* Annette Kjær Ersbøll, PhD, MSc* Anders Green, PhD, DMSc, MD†‡ Jesper Hallas, PhD, DMSc, MD§ and Lau Caspar Thygesen, PhD, MSc*

---

**Background:** Psychiatric comorbidity might modify the disease course adversely in patients with inflammatory bowel disease (IBD). Treatment options include antidepressants, which, apart from improving mood, have anti-inflammatory properties that might modify the disease course. This nationwide study aimed to examine the influence of antidepressants on the disease course among patients with ulcerative colitis (UC) and Crohn’s disease (CD).

**Methods:** Patients registered with an incident diagnosis of CD or UC in the Danish National Patient Register (2000–2017) were included. Information on antidepressant use and proxy measures of disease activity (health care and drug utilization) was extracted from national population registers. Poisson regression was performed to estimate disease activity rates by antidepressant use adjusted for confounders. Furthermore, the analyses were performed stratified by IBD subtype and type of antidepressants.

**Results:** A total of 42,890 patients were included (UC: 69.5%; CD: 30.5%). When adjusted for confounders, a lower incidence rate of disease activity was found among antidepressant users compared with nonusers in both CD (incidence rate ratio [IRR], 0.75; 95% confidence interval [CI], 0.68–0.82) and UC (IRR, 0.90; 95% CI, 0.84–0.95) patients. Further, markedly lower rates of disease activity were found among CD (IRR, 0.51; 95% CI, 0.43–0.62) and UC (IRR, 0.67; 95% CI, 0.59–0.75) patients with no use of antidepressants before IBD onset.

**Conclusions:** In this nationwide study, antidepressant use was found to be beneficial on the disease course among patients with UC and CD, particularly in patients with no use of antidepressants before IBD onset. Randomized controlled trials are warranted to investigate the potential of antidepressants being an adjunct treatment to conventional IBD therapy.

**Key Words:** inflammatory bowel disease, Crohn’s disease, ulcerative colitis, antidepressants, disease course

---

**INTRODUCTION**

Psychiatric comorbidity may modify the disease course adversely among patients with inflammatory bowel disease. Psychiatry and depression when required. Apart from improving mood, it is observed that the anti-inflammatory properties of antidepressants may influence the inflammatory response directly. Other research suggests a bidirectional relationship between IBD activity and psychological disorders, that is, the “brain–gut axis,” wherein relief of depression and anxiety symptoms by the use of antidepressants potentially affects gut health. The brain–gut interaction has previously been demonstrated in other gastrointestinal disorders such as irritable bowel syndrome and functional dysplasia.

Thus, a recent systematic review indicated that treatment with antidepressants may have a beneficial effect on IBD activity. However, the vast majority of existing clinical studies are hampered by methodological limitations in terms of small and selected IBD populations and short observation periods. Moreover, existing studies have mainly used symptom-based scoring systems and not objective markers when assessing IBD activity with the limitation of subjective interpretations. Hence, based on existing guidelines.

---

Received for publications May 31, 2018; Editorial Decision November 7, 2018. From the *National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark; †OPEN (Odense Patient data Explorative Network), Odense University Hospital/University of Southern Denmark, Odense, Denmark; ‡Institute of Applied Economics and Health Research, Copenhagen, Denmark; †Department of Clinical Pharmacology, University of Southern Denmark, Odense, Denmark

Conflict of interest: The authors MSK, TMK, AKE, AG, JH and LCT declare no conflict of interest. AG is partner and scientific director at ApEHR but has not received any payment for the submitted article and declares no activities that might have influenced the submitted article.

Supported by: This article is based on data obtained for a separate study conducted by Applied Economics and Health Research (ApEHR) and funded by Merck Sharp & Dohme Corp.

Address correspondence to: Marie Skov Kristensen, MSc, RN, National Institute of Public Health, University of Southern Denmark, Studiestræde 6, 2nd floor, 1455 Copenhagen K, Denmark (marsk@si-folkesundhed.dk).

© 2018 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

doi: 10.1093/ibd/izy367
Published online 14 December 2018
evidence, no firm conclusions can be made about the effects of antidepressants on the course of IBD.

In Denmark, national registers offer a unique opportunity to provide information on health care utilization and drug use in the entire IBD population residing in Denmark, with a universal health care system providing access to the same national health insurance for all citizens. Using a population-based cohort design to study how treatment with antidepressants may influence the IBD course minimizes selection bias. Thus, the aim of this study was to examine the influence of antidepressants on the disease course among patients with IBD stratified by IBD subtype (ie, ulcerative colitis [UC] and Crohn’s disease [CD]) using the Danish nationwide health registers.

**METHODS**

**Study Population and Design**

This study was a population-based cohort study with prospectively collected data.

The study population comprised all patients registered with an incident (first-ever) primary diagnosis of UC (International Classification of Diseases [ICD] version 8: 56319, 56904, ICD-10: K51) or CD (ICD-8: 56300–56302, 56308, 56309, ICD-10: K50), depending on which IBD diagnosis appeared first in the Danish National Patient Register,

**Outcome Measures**

Being surrogate markers of disease relapse, the primary outcomes were defined as either (1) hospitalization with IBD as the primary diagnosis; (2) surgery associated with IBD (NOMESCO: JFB, JFB2–JFB6 [including all subcodes], JFB96, JFB97, and JFH [including all subcodes]) as the primary operation code; or (3) step-up medication in terms of a redeemed prescription of corticosteroids (ATC: H02AB, A07EA01–A07EA07) or initiation of anti-TNF treatment (procedure code:
RESULTS

Patient Characteristics

A total of 44,560 patients who were registered with a first-time diagnosis of IBD during 2000–2017 were eligible for study inclusion. Patients who had undergone IBD-related surgery (n = 692) or been treated with anti-TNF (n = 299) before IBD onset were excluded. In addition, patients who emigrated (n = 121) or died (n = 558) within the 180 days of lag period from the date of IBD onset were excluded. Thus, 42,890 patients were included in the study, contributing 144,191 person-years of follow-up.

The majority of the study population was diagnosed with UC (69.5%). Patients with CD and UC did not differ substantially regarding sex or comorbidity pattern, whereas a difference in median age at IBD onset of 8 years was found between patients with UC (42 years) and CD (34 years) (Table 1).

Antidepressant Treatment and Disease Course

In total, 28% of the study population redeemed at least 1 prescription of antidepressants. Of these, the majority redeemed at least 1 prescription before IBD onset (79%) (Table 1). After a 180-day lag period from the date of IBD onset, a total of 94,277 antidepressant prescriptions were redeemed in the study period.

Patients with IBD currently exposed to antidepressants had a significantly lower relapse rate (IRR, 0.85; 95% CI, 0.81–0.90) compared with patients not currently exposed to AD after adjusting for confounders. Analyzing the interaction between the exposure and IBD subtype showed that the association was more pronounced in patients with CD (IRR, 0.75; 95% CI, 0.68–0.82) compared with UC patients (IRR, 0.90; 95% CI, 0.84–0.95; P interaction < .001) (Table 2). As illustrated in Figure 1, CD (IRR, 0.51; 95% CI, 0.43–0.62) and UC (IRR, 0.67; 95% CI, 0.59–0.75) patients with no prior use of antidepressants before IBD onset had a favorable influence on the disease course when exposed to antidepressants compared with nonusers.

In analyses stratified by subtype of antidepressant among patients with no prior use of antidepressants before IBD onset, both monotherapy and mixed use were associated with a significantly lower relapse rate among patients with UC and CD compared with nonusers. This finding was not significant for patients exposed to mirtazapine, however; the same trend was found (Table 2).

Step-up Medication, IBD-Related Hospitalization, and Surgery

When specifying the analyses by outcome related to disease course, a significantly lower risk for initiating step-up medication with corticosteroids and anti-TNF treatment was demonstrated for UC and CD patients exposed to antidepressants compared with nonusers (Table 3). Similarly, a lower risk for IBD-related hospitalization was observed in UC and CD.
patients exposed to antidepressants compared with nonusers; however, this finding was insignificant. The analyses stratified by IBD subtype also suggested that patients with UC exposed to antidepressants had a lower risk of IBD-related surgery compared with nonusers. Conversely, patients with CD exposed to antidepressants compared with nonusers had an increased risk for IBD-related surgery, yet these findings related to IBD surgery were insignificant (Table 3).

**Demographic Features and Psychiatric Comorbidity**

Treatment with antidepressants had a more pronounced beneficial influence on the disease course in UC and CD patients age 15–59 years and among CD patients age 80+ years compared with antidepressant users among younger and older age groups (Fig. 1). When stratified by sex, it was observed that both sexes among UC and CD patients exposed to antidepressants had a significantly lower relapse rate compared with nonusers. Finally, among UC and CD patients who had no previous diagnosis of anxiety and/or depression, treatment with antidepressants had a significantly favorable influence on the disease course compared with nonusers (Fig. 1).

**DISCUSSION**

This nationwide study of IBD patients demonstrated that patients with exposure to antidepressants had a significantly lower relapse rate compared with nonusers. The most favorable influence of antidepressant treatment was observed among patients with CD compared with UC patients. This favorable influence of antidepressant treatment on the IBD course was found regardless of being exposed to monotherapy or mixed use.
In this study, we observed that 28% of the study population redeemed at least 1 prescription of antidepressants at some point in time. This finding is comparable with a previous Finnish study demonstrating that patients with IBD have an increased use of antidepressants compared with the general population (28% vs 19%).

To our knowledge, this study is the first to demonstrate that the beneficial influence of antidepressants on the risk of disease relapse is more pronounced in patients with no prior history of antidepressant treatment compared with patients with a previous use of antidepressants. Two possible hypotheses may explain this. First, patients treated with antidepressants before IBD onset may not benefit further from the potential anti-inflammatory effect of the drug when treated for psychiatric comorbidity after IBD onset. Second, patients treated with antidepressants before IBD onset may be more vulnerable during the disease course due to mental challenges unrelated to IBD, leading to an increased risk of disease relapse.

We are not able to differentiate between whether the beneficial influence of antidepressants on IBD course derives from mood improvements or the effect of the anti-inflammatory properties of the drug. Previous research has shown that antidepressants affect the level of pro-inflammatory cytokines such as interleukin and tumor necrosis factor-α, which have been found to be involved in the pathogenesis of IBD. Hence, decreased levels of pro-inflammatory cytokines may explain the observed favorable influence on the course of IBD.

### TABLE 2. The Course of Disease (Risk of IBD-Related Hospitalization, Surgery, Step-up Medication) During Periods in Which Patients With Crohn’s Disease and Ulcerative Colitis, Respectively, Were Exposed to Antidepressants Compared With Periods in Which They Were Unexposed

| IBD Type | Exposure | Person-Years | No. of Outcomes | Incidence Rate per 100 Person-Years | Incidence Rate Ratioa | 95% CI |
|----------|----------|--------------|----------------|-------------------------------------|-----------------------|-------|
| **Main model** | | | | | | |
| IBD | Any antidepressant | No | 131,408 | 22,254 | 16.9 | 1 (ref) |
| | | Yes | 12,783 | 2057 | 16.1 | 0.85 | 0.81–0.90 |
| CD | Any antidepressant | No | 33,563 | 7397 | 22.0 | 1 (ref) |
| | | Yes | 3465 | 588 | 17.0 | 0.75 | 0.68–0.82 |
| UC | Any antidepressant | No | 97,845 | 14,857 | 15.2 | 1 (ref) |
| | | Yes | 9318 | 1469 | 15.8 | 0.90 | 0.84–0.95 |
| **Stratified by type of antidepressant among patients with no use of antidepressant before IBD onset** | | | | | | |
| CD | None exposed | 33,563 | 7397 | 22.0 | 1 (ref) |
| | SSRI | 888 | 54 | 6.1 | 0.23 | 0.14–0.38 |
| | SNRI | 156 | 10 | 6.4 | Not possible to estimateb |
| | TCA | 37 | 4 | 10.8 | Not possible to estimateb |
| | Mirtazepine | 78 | 4 | 5.2 | 0.28 | 0.04–1.97 |
| | Other antidepressantsc | 3 | <3 | 73.4 | Not possible to estimateb |
| | Mixed use of antidepressants | 2304 | 514 | 22.3 | 0.60 | 0.49–0.73 |
| UC | None exposed | 97,845 | 14,857 | 15.2 | 1 (ref) |
| | SSRI | 2144 | 139 | 6.5 | 0.23 | 0.15–0.35 |
| | SNRI | 412 | 22 | 5.3 | 0.13 | 0.03–0.51 |
| | TCA | 100 | <3 | 3.0 | Not possible to estimateb |
| | Mirtazepine | 131 | 11 | 8.4 | 0.72 | 0.32–1.61 |
| | Other antidepressants | 12 | <3 | 0.0 | Not possible to estimateb |
| | Mixed use of antidepressants | 6519 | 1294 | 19.8 | 0.80 | 0.70–0.91 |

The analyses were stratified by type of antidepressant treatment.

Abbreviations: CD, Crohn’s disease; IBD, inflammatory bowel disease; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; UC, ulcerative colitis.

a All models are adjusted for age, sex, comorbidity, chronic obstructive pulmonary disorder (proxy variable for smoking), previous diagnosis of anxiety and/or depression, IBD subtype, and calendar year.

b Due to small sample size.

c Other antidepressants: bupropion, buspirone, and agomelatine.
be that antidepressants play a role in affecting the brain–gut interaction.7

Some previous studies among IBD populations support the main finding of the present study,21–23 whereas other studies did not find significantly decreased disease activity among IBD antidepressant users.24,25 However, the vast majority of the previous studies9 are hampered by small samples (<100 patients), short observation periods (<2 years), and the use of inconsistent outcome measures, making it difficult to make any direct comparisons with the findings of our study. Of the existing literature, few small randomized controlled trials22,25 have been conducted within this field investigating the effects of SSRI and SNRI, respectively, on the disease course among patients with IBD. These studies were based on underpowered samples, and the findings pointed in opposite directions. Evidence from observational studies including the present study is based on larger sample sizes, increasing the statistical power to examine the association between antidepressant use and IBD activity. However, the causal interpretation from these studies is limited by the observational design. Future trials examining the efficacy of antidepressants on the IBD course are warranted. Moreover, IBD trials excluding individuals with depression or anxiety would increase our understanding of the mechanism of action behind the potential demonstrated effect.

**Strength and Limitations of the Study**

The main strength of this nationwide study is the inclusion of a large unselected IBD population with a long follow-up period, which allows for capturing the long-term influence of antidepressants.

Comparisons with pathology registers have demonstrated a validity of 97% for CD and 90% for UC diagnoses in the Danish National Patient Register.26 Prescription redemptions of antidepressants registered in the Danish National Prescription

---

**FIGURE 1.** The course of disease during periods in which patients with Crohn’s disease and ulcerative colitis were exposed to antidepressants compared with periods in which they were unexposed. The analyses were stratified by sex, age, psychiatric diagnoses (anxiety and depression), and previous antidepressant use.
Registry were also found to be nearly complete, with 99% of the sales being person-identifiable. Redeemed antidepressants may, however, not fully reflect actual intake, which is a limitation of this study. Further, specification of antidepressant by doses was not possible, as the potency of the drugs does not necessarily correspond to a day’s supply. Moreover, when specifying the analyses by subtype of antidepressant, several categories were influenced by small numbers, making it difficult to make a complete interpretation of these findings. Safety issues including adverse events of antidepressants were not addressed in this study, but evidence suggests that IBD patients treated with antidepressants may experience side effects commonly. Information on nonpharmacological treatment for presumed depression or anxiety was not available from the national population registers. Hence, it was not possible to rule out potential confounding from nonpharmacological treatment on the study results.

Proxy measures of IBD activity were solely identified by register data, which is a limitation of this study. Clinical data on IBD symptoms and objective biomarkers of inflammation (e.g., cytokines or calprotectin) would have improved the validity of the outcome measures. Nevertheless, it is evident that requirement of step-up medication (corticosteroids and anti-TNF) and hospitalization related to IBD reflect moderate to severe disease activity, and a lag period of 180 days before study enrollment increased the probability that the patients were in remission when included. Thus, the findings may not be generalizable to IBD patients with mild disease activity.

Moreover, this study is limited by a lack of information on medication adherence, as nonadherence to IBD treatment is found to be a significant trigger for disease flare. Thus, it is suggested that psychological distress is a factor that is significantly associated with medication nonadherence. Information regarding anxiety and depression was only available from the Danish National Patient Register. This suggests that only the most severe cases with anxiety and depression were registered in the study. Though we used chronic obstructive pulmonary disease as a proxy measure of smoking, residual confounding cannot be ruled out. Thus, it may be presumed that information on the heaviest smokers was included in this study. Finally, confounding by indication cannot be ruled out, meaning that users of antidepressants may be different from nonusers according to unmeasured confounding.

**Implications for Practice**

As no cure exists for IBD, a sustained focus on optimizing treatment contributing to maintaining remission is crucial for patients. Antidepressants have the potential to be an adjuvant treatment to the conventional therapy for IBD, similar to...
treatment for irritable bowel syndrome. Trials in patients with IBD are needed to confirm the role of antidepressants in modifying the disease course. Despite the high prevalence of anxiety and depression, it is found that IBD patients often do not receive appropriate psychiatric treatment. A holistic approach should be applied when screening IBD patients systematically for symptoms of anxiety and depression. Besides offering antidepressant treatment and/or psychotherapy when required, clinicians must be aware that perceived stigma and perception of illness severity are found to be barriers to adherence to antidepressants. In clinical decision-making, potential adverse events of the drug should also be taken into account.

**CONCLUSIONS**

This study showed that treatment with antidepressants may have a beneficial influence on the disease course in patients with IBD. This finding was most pronounced in patients with CD and in patients with no prior history of antidepressant treatment. The underlying mechanism of action explaining this association is beyond the scope of this study, and randomized controlled trials are warranted to investigate the potential of antidepressants as an adjunct treatment to conventional IBD therapy.

**REFERENCES**

1. Mikocka-Walus A, Pittet V, Rossel JB, von Kanel R; Swiss IBD Cohort Study Group. Symptoms of depression and anxiety are independently associated with clinical recurrence of inflammatory bowel disease. *Clin Gastroenterol Hepatol.* 2016;14:829–835.e1.

2. Porcelli P, Leoci C, Guerra V. A prospective study of the relationship between disease activity and psychologic distress in patients with inflammatory bowel disease. *Scand J Gastroenterol.* 1996;31:792–796.

3. Mikocka-Walus AA, Turnbull DA, Moulding NT, et al. Does psychological status influence clinical outcomes in patients with inflammatory bowel disease (IBD) and other chronic gastroenterological diseases: an observational cohort prospective study. *Biopsychosoc Med.* 2008;2:11. doi:10.1186/1751-0759-2-11

4. Häuser W, Moser G, Klose P, Mikocka-Walus A. Psychosocial issues in evidence-based guidelines on inflammatory bowel diseases: a review. *World J Gastroenterol.* 2014;20:3663–3671.

5. Kast RE. Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating leptin and desipramine administration on cytokine release in C57BL/6 mice. *Psychoneuroendocrinology.* 2000;25:785–797.

6. Strober W, Fuss IJ. Promflammatory cytokines in the pathogenesis of inflammatory bowel diseases. *Gastroenterology.* 2011;140:1756–1767.

7. Goodhand JR, Greig FI, Koodun Y, et al. Do antidepressants influence the disease course in inflammatory bowel disease? A retrospective case-matched observational study. *Inflamm Bowel Dis.* 2012;18:1232–1239.

8. Daghaghazadeh H, Naja F, Afshar H, et al. Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: a double-blind controlled study. *J Res Med Sci.* 2015;20:595–601.

9.iskandar HN, Cassell B, Kamuri N, et al. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. *J Clin Gastroenterol.* 2014;48:423–429.

10. Yanartas O, Kani HT, Bicakci E, et al. The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease. *J Crohns Colitis*. 2014;8:79–88.

11. Kast RE. Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating leptin and desipramine administration on cytokine release in C57BL/6 mice. *Psychoneuroendocrinology.* 2000;25:785–797.

12. Goodhand JR, Greig FI, Koodun Y, et al. Do antidepressants influence the disease course in inflammatory bowel disease? A retrospective case-matched observational study. *Inflamm Bowel Dis.* 2012;18:1232–1239.

13. Fonager K, Sorensen HT, Rasmussen SN, et al. Assessment of the diagnoses of crohn’s disease and ulcerative colitis in a Danish hospital information system. *Scand J Gastroenterol.* 1996;31:154–159.

14. Schmidt M, Hallas J, Laursen M, Friis S. Data resource profile: Danish online drug use statistics (MEDSTAT). *Int J Epidemiol.* 2016;45:1401–1402g.

15. Melesse DY, Lix LM, Nugent Z, et al. Estimates of disease course in inflammatory bowel disease using administrative data: a population-level study. *J Crohns Colitis*. 2017;11:562–570.

16. Feagins LA, Iqbal R, Spechler SJ. Case-control study of factors that trigger inflammatory bowel disease. *Aliment Pharmacol Ther.* 2013;45:1401–1402g.

17. Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. *Am J Gastroenterol.* 2010;105:525–539.

18. Ford AC, Quigley EMM, Lacy BE, et al. The effect of repeated amitriptyline and desipramine administration on cytokine release in C57BL/6 mice. *Psychoneuroendocrinology.* 2000;25:785–797.

19. Kubera M, Holan V, Mathison R, Maas M. The effect of repeated amitriptyline and desipramine administration on cytokine release in C57BL/6 mice. *Psychoneuroendocrinology.* 2000;25:785–797.

20. Strober W, Fuss IJ. Promflammatory cytokines in the pathogenesis of inflammatory bowel diseases. *Gastroenterology.* 2011;140:1756–1767.